1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow GDC-4198: new trials by email Literature Review of GDC-4198 trials Research Report on GDC-4198
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer GDC-4198, Giredestrant, Abemaciclib - Breast Cancer | Phase 1 / Phase 2 | Recruiting | Genentech, Inc. | 285 | 2025-10-07 | 2026-10-26 |
Breast Neoplasms (1)
Genentech, Inc. (1)
Australia (1) · Brazil (1) · Canada (1) · China (1) · France (1) · Germany (1) · Italy (1) · South Korea (1) · Spain (1) · United States (1)
2025 (1)